Food and Drug Administration (FDA) is reconsidering its decision to remove tirzepatide injection, a glucagon-like peptide-1 medication, from the official shortage list. The decision comes after FDA was sued by compounding pharmacies and a trade organization representing compounding pharmacies, arguing that the drug from Eli Lilly is still in short supply. FDA’s motion to stay the court proceeding and remand the case back to itself was granted. The agency has requested that plaintiffs provide additional information on the drug to assess its availability. As of October 2, 2024, dulaglutide, semaglutide, and liraglutide injections continue to be in shortage.